Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Sean Tan, Ella Spear, Nikhita Sane, Adam J. Nelson, Nitesh Nerlekar, Eva Segelov, Stephen J. Nicholls

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs. [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)1043-1046
Number of pages4
JournalJournal of Human Hypertension
Issue number11
Publication statusPublished - Nov 2023

Cite this